Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

1.

Risks factors for highly unstable response to oral anticoagulation: a case-control study.

Palareti G, Legnani C, Guazzaloca G, Lelia V, Cosmi B, Lunghi B, Marchetti G, Poli D, Pengo V; ad hoc Study Group of the Italian Federation of Anticoagulation Clinics*.

Br J Haematol. 2005 Apr;129(1):72-8.

PMID:
15801958
[PubMed - indexed for MEDLINE]
2.

Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of portable prothrombin time monitor (COAGUCHECK).

Cosmi B, Palareti G, Carpanedo M, Pengo V, Biasiolo A, Rampazzo P, Morstabilini G, Testa S.

Haematologica. 2000 Aug;85(8):826-31.

PMID:
10942929
[PubMed - indexed for MEDLINE]
Free Article
3.

Genetic and environmental risk factors for oral anticoagulant overdose.

Verstuyft C, Robert A, Morin S, Loriot MA, Flahault A, Beaune P, Funck-Brentano C, Jaillon P, Becquemont L.

Eur J Clin Pharmacol. 2003 Mar;58(11):739-45. Epub 2003 Feb 18.

PMID:
12634980
[PubMed - indexed for MEDLINE]
4.

Switching from acenocoumarol to warfarin in patients with unstable anticoagulation and its effect on anticoagulation control.

Undas A, Cieśla-Dul M, Zółciński M, Tracz W.

Pol Arch Med Wewn. 2009 Jun;119(6):360-5.

PMID:
19694217
[PubMed - indexed for MEDLINE]
Free Article
5.

Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial.

Laporte S, Quenet S, Buchmüller-Cordier A, Reynaud J, Tardy-Poncet B, Thirion C, Decousus H, Mismetti P.

Thromb Haemost. 2003 Mar;89(3):458-67.

PMID:
12624628
[PubMed - indexed for MEDLINE]
6.

Acenocoumarol stabilization is delayed in CYP2C93 carriers.

Schalekamp T, van Geest-Daalderop JH, de Vries-Goldschmeding H, Conemans J, Bernsen Mj Mj, de Boer A.

Clin Pharmacol Ther. 2004 May;75(5):394-402.

PMID:
15116052
[PubMed - indexed for MEDLINE]
7.

[Major closed-space bleeding in patients on anticoagulation with acenocoumarol (TAO) or non-fractionned heparin(HS): a case-control study].

Martínez Lacasa J, Juan N, Juliá J, Rodríguez-Carballeira M, de Diego I, Soto R, Garau J.

An Med Interna. 2008 Jan;25(1):9-14. Spanish.

PMID:
18377188
[PubMed - indexed for MEDLINE]
8.

Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.

Beinema M, Brouwers JR, Schalekamp T, Wilffert B.

Thromb Haemost. 2008 Dec;100(6):1052-7. Review.

PMID:
19132230
[PubMed - indexed for MEDLINE]
9.

Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.

Miao L, Yang J, Huang C, Shen Z.

Eur J Clin Pharmacol. 2007 Dec;63(12):1135-41. Epub 2007 Sep 27.

PMID:
17899045
[PubMed - indexed for MEDLINE]
10.

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.

Schalekamp T, Oosterhof M, van Meegen E, van Der Meer FJ, Conemans J, Hermans M, Meijerman I, de Boer A.

Clin Pharmacol Ther. 2004 Nov;76(5):409-17.

PMID:
15536456
[PubMed - indexed for MEDLINE]
11.

Determination of bleeding risk using genetic markers in patients taking phenprocoumon.

Hummers-Pradier E, Hess S, Adham IM, Papke T, Pieske B, Kochen MM.

Eur J Clin Pharmacol. 2003 Jul;59(3):213-9. Epub 2003 May 1.

PMID:
12728288
[PubMed - indexed for MEDLINE]
12.

[Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].

Márk L, Márki-Zay J, Fodor L, Kondacs A, Paragh G, Katona A.

Orv Hetil. 2005 Apr 17;146(16):739-43. Hungarian.

PMID:
15889670
[PubMed - indexed for MEDLINE]
13.

Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Stehle S, Kirchheiner J, Lazar A, Fuhr U.

Clin Pharmacokinet. 2008;47(9):565-94. Review.

PMID:
18698879
[PubMed - indexed for MEDLINE]
14.

The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients.

Montes R, Ruiz de Gaona E, Martínez-González MA, Alberca I, Hermida J.

Br J Haematol. 2006 Apr;133(2):183-7.

PMID:
16611310
[PubMed - indexed for MEDLINE]
15.

An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.

Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL.

Thromb Haemost. 2008 Aug;100(2):229-39.

PMID:
18690342
[PubMed - indexed for MEDLINE]
16.

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.

Visser LE, van Vliet M, van Schaik RH, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH.

Pharmacogenetics. 2004 Jan;14(1):27-33.

PMID:
15128048
[PubMed - indexed for MEDLINE]
17.

Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.

Verstuyft C, Morin S, Robert A, Loriot MA, Beaune P, Jaillon P, Becquemont L.

Pharmacogenetics. 2001 Nov;11(8):735-7.

PMID:
11692083
[PubMed - indexed for MEDLINE]
18.

Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions.

Muszkat M, Blotnik S, Elami A, Krasilnikov I, Caraco Y.

Clin Ther. 2007 Mar;29(3):427-37.

PMID:
17577464
[PubMed - indexed for MEDLINE]
19.

The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study.

Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD, Brensinger CM, Newcomb CW, Samaha FF, Gross R.

Arch Intern Med. 2007 Feb 12;167(3):229-35.

PMID:
17296877
[PubMed - indexed for MEDLINE]
20.

A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol).

Pattacini C, Manotti C, Pini M, Quintavalla R, Dettori AG.

Thromb Haemost. 1994 Feb;71(2):188-91.

PMID:
8191397
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk